ZAPI GROUP Showcases New Solutions in Material Automation at LogiMAT 2024
ZAPI GROUP, a global leader in electrification, announced today it is showcasing its solutions for the material handling and electrification industries at LogiMAT 2024. At the event, ZAPI GROUP is announcing the expansion of BlueBotics, a ZAPI GROUP company and leader in autonomous navigation technology. BlueBotics has partnered with Pramac, a leading global supplier of warehouse material handling equipment, and expanded its ANT server mission and fleet management software. These milestones bolster ZAPI GROUP's standing as a comprehensive autonomous navigation and AGV fleet management provider for electrification.
"The expansion of BlueBotics is an exciting milestone as ZAPI GROUP continues to grow its capabilities to serve the global AGV and material handling sectors," noted Lloyd Gomm, Global Marketing Director at ZAPI GROUP. "BlueBotics’ consistent innovation in navigation software enables the company to broaden the spectrum of solutions and integrated systems available to our OEM customers. LogiMAT presents an opportunity to showcase these developments and other product innovations with the industry.”
The ZAPI GROUP is exhibiting at LogiMAT 2024 in Stuttgart from March 19 - 21 in hall 6, booth 6C61. They provide a wide array of capabilities for OEMs with a range of electrification and automation solutions for material handling machines and robots, including inverters and controllers, electric motors, high-frequency battery chargers and accessories. Its companies leading innovation across AGV and material handling sectors include BlueBotics, Zapi, Inmotion Technologies, Delta-Q Technologies, Zivan, Schabmüller, 4E Consulting, Best Motor and ZTP.
At the ZAPI GROUP booth at LogiMAT, the BlueBotics team is announcing the agility of its ANT server fleet management software to control not only more than 100 “ANT driven” customer vehicles but also now VDA 5050-compliant AGVs and AMRs. The company will also demo Pramac’s X-ACT HYBRIX robot, a new line of X-ACT mobile logistics robots powered by BlueBotics’ latest version of its software, as part of its on-stand multi-brand AGV/AMR fleet demo.
“We are thrilled to further expand our suite of autonomous navigation and AGV fleet management solutions,” said BlueBotics’ CEO, Dr. Nicola Tomatis. “BlueBotics has a proven track record of developing autonomous solutions for a variety of mobile robotic platforms. These solutions continue to complement ZAPI GROUP's existing system integration capabilities, advance its electrification mission and enhance OEMs’ access to robust solutions for material handling automation.”
The ZAPI GROUP recently hosted industry leaders at its annual virtual conference, The Future of Electrification. This was the company’s third year hosting the event aimed to drive education and innovations for electrification across its key industries.
To learn more about ZAPI GROUP and its companies, visit them at LogiMAT 2024 (hall 6, stand 6C61).
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, high-frequency battery chargers, and autonomous navigation software for application in full-electric and hybrid vehicles. As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1700 employees worldwide with total annual revenue of more than 700 million US dollars.
For more information about the group, visit www.zapigroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319748003/en/
Contact information
AnnMarie Carson, Communiqué PR
Phone: (206) 282-4923 ext. 119
Email: zapigrouppr@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom